2,5-dimethoxyamphetamine

**Description:** 2,5-Dimethoxyamphetamine (commonly abbreviated as "DMA" or "2,5-DMA") is a synthetic compound in the substituted amphetamine class. It is structurally related to amphetamine and phenethylamines and is the parent compound of the DOx series of drugs. First synthesized in the late 1930s by Richard Baltzly and Johannes S. Buck[3], it has been studied for its pharmacological properties but has no accepted medical use. **Mechanism of Action:** At tested doses (80–160 mg orally), it produces mild stimulant-like and sympathomimetic effects such as mydriasis (pupil dilation) and increased heart rate but lacks significant psychedelic activity[1][3][4][7]. Its primary mechanism involves low-potency partial agonism at serotonin receptors—specifically the serotonin receptor subtype known as "serotonin receptor 2A"—but it does not significantly bind to monoamine transporters[3][7]. **Legal Status & Use:** It is classified as a Schedule I controlled substance in the United States due to its structural similarity to other psychoactive amphetamines and lack of approved medical use[2].

Other names

1-(2,5-dimethoxyphenyl)-2-aminopropaneBenzeneethanamine, 2,5-dimethoxy-alpha-methyl-2,5-dimethoxyamphetamine hydrochloride2,5-dimethoxyamphetamine hydrochloride (+/-)-isomer2,5-dimethoxyamphetamine hydrochloride (R)-isomer2,5-dimethoxyamphetamine hydrochloride (S)-isomer2,5-dimethoxyamphetamine oxalate(1:1), (+/-)-isomer2,5-dimethoxyamphetamine sulfate(2:1)DMA